- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- News News
- Join Join
In the December 2020 Issue:
- UN Recognizes Medical Value of Cannabis
- Landmark MORE Act Passes House, Moves to Senate
- Cannabis Research Act Passes House
- ASA Updates Medical Cannabis Travel Guide
- ASA Blog Covers Veterans Medical Cannabis Bills
- ASA Year-End Review Webinar
- Patient Focused Certification Continues Despite Pandemic
- New ASA Podcasts Available
- ASA Year-End Review Webinar
- Activist Profile: Kenzi Riboulet-Zemouli, Barcelona, Spain
- Action Alert: Contact Your Rep on MORE Act Vote
UN Recognizes Medical Value of Cannabis
In a historic decision with global implications for drug policy, the United Nations Commission on Narcotic Drugs (CND) has reclassified cannabis to recognize its medical value. The 53 member states of the CND voted 27 to 25 with one abstention in favor of adopting the World Health Organization’s (WHO) recommendations to remove cannabis and its resin from the most restricted international category, Schedule IV. The U.S. voted in favor of the change.
Under the UN Single Convention on Narcotic Drugs of 1961, Schedule IV drugs are classified as highly dangerous substances of abuse with no therapeutic value. This classification corresponds with Schedule I under the U.S. Controlled Substances Act of 1970.
ASA and its program the International Medical Cannabis Patients Coalition (IMCPC) have been fighting to deschedule cannabis at the United Nations for over a decade. In 2016 ASA and the IMCPC produced an independent critical review of the science on cannabis that was delivered to the UN, showing that cannabis and its derivatives were improperly classified. Following that, the WHO’s Expert Committee on Drug Dependence (ECDD) began a pre-review of the science and policies related to medical cannabis.
As an independent, scientific advisory body, the ECDD was able to conduct a rigorous, evidence-based, multi-year review that resulted in the WHO recommending to the UN that cannabis and its resin be removed from Schedule IV.
“This is a momentous occasion for cannabis advocates everywhere who have been fighting for this change for many years,” said Steph Sherer, president and founder of ASA and the IMCPC. “The WHO’s function is to give us scientific guidance, and countries that voted against the WHO’s recommendations are playing politics instead of using rational policy.”
The CND decision to reclassify puts pressure on US federal agencies and elected officials to reconsider the 50-year-old law on cannabis, which does not recognize the differences between medical and recreational use and makes activities authorized by state medical cannabis programs federal crimes.
Landmark MORE Act Passes House of Representatives
ASA Helps Secure Veterans’ Language in Bill
In a historic vote, the U.S. House of Representatives passed the bipartisan Marijuana Opportunity Reinvestment and Expungement Act (MORE Act). The bill moves to the Senate for consideration. If enacted, the MORE Act would remove cannabis from drug control scheduling and enable a national approach to safe access.
HR 3884, which was introduced by Rep. Jerrold Nadler (D-NY), would decriminalize cannabis at the federal level. Among other benefits, it would allow patients to travel across state lines with their cannabis without fear of punitive law enforcement intervention, fines, or jail time.
ASA worked closely with Rep. Lou Correa’s (D-CA) office to add language as the bill was brought to the House floor that authorizes research on the mental and physical health applications of cannabis to veterans. The amendment incorporated provisions from Rep. Correa’s VA Medical Cannabis Research Act of 2019, HR 712, which had not received a vote.
“ASA has been working 18 years for this,” said ASA executive director Debbie Churgai. “The MORE Act is a signal to medical cannabis patients that their voices have finally been heard in Congress. Now we need the Senate to take the next step.”
The MORE Act would introduce federal oversight over key components of medical cannabis policy that states have struggled with, such as laboratory testing, labeling standards, and businesses practices.
“The 4.5 million registered cannabis patients in the US have been denied rights because of the federal government’s classification of cannabis as having no medical use,” said Churgai. “ASA has worked with legislators to improve the MORE Act and hope to build on this landmark action until all the needs of medical cannabis patients are met at the federal level.”
House passage of the MORE Act sends it to the Senate for consideration. If the Senate does not take action before the 116th Congress wraps up work for the year, the bill’s sponsors will have to reintroduce the bill in the new Congress that begins in January.
House Passes the Medical Marijuana Research Act
On December 9, the U.S. House of Representatives passed by a voice vote HR 3797, the Medical Marijuana Research Act of 2019, which would remove many existing barriers to research that can benefit patients. The bill has been sent to the Senate.
If enacted, the bipartisan legislation introduced by Reps. Earl Blumenauer (D-OR) and Andy Harris (R-MD) would enable researchers to study the cannabis products that patients and consumers are using in state programs. Currently, researchers must use cannabis supplied by the National Institute on Drug Abuse (NIDA), which has been criticized for being of low quality and differs substantially from what consumers are using today. The supply of research cannabis from NIDA has also been limited and difficult to obtain.
The act would direct the U.S. Department of Health and Human Services to issue a report on the results of medical cannabis research.
The Drug Enforcement Administration (DEA) is being sued by a number of researchers who have applied for licenses to cultivate research cannabis but not received them. Despite court rulings finding more research on cannabis to be in the public interest and directing the DEA to issue more licenses, the application process has faced bureaucratic delays.
“As commercially available cannabis products continue to expand in 35 states, it is more important than ever for the federal government to allow research using the products that patients are using every day,” said ASA Executive Director Debbie Churgai.
To go into effect, the Medical Marijuana Research Act will have to pass the Senate during the lame duck session between now and when the new Congress takes over in January.
ASA Blog Covers Veterans Medical Cannabis Bills
Last month, ASA’s blog included an overview of congressional actions and bills affecting safe access for veterans. Veterans comprise a large proportion of the roughly 4.4 million cannabis patients in the U.S. who are stuck between conflicting federal and state cannabis policies. Because many veterans receive health care through the Veterans Health Administration, they face more obstacles than many patients.
ASA’s blog covers the bills the 116th Congress considered and legislation we might see when the new congress convenes in January. All congressional actions on safe access for veterans have taken a bipartisan approach, attracting significantly more Republican support than cannabis-related legislation where veterans are not directly affected.
See the blog for more on HR 712 - the VA Medicinal Cannabis Research Act of 2019 and HR 1647 - the Veterans Equal Access Act. For more information on veteran policy issues and ways to engage with ASA in supporting them, check out ASA’s Veterans and Medical Cannabis Roundtable Discussion that took place on November 10, 2020.
Patient Focused Certification Continues Despite Pandemic
The pandemic prevented ASA’s Patient Focused Certification staff from attending the conferences and events, but PFC was able to participate in a number of notable online events. The International Cannabis Bar Association, MJBiz, ASTM, Analytical Cannabis, Abilities Expo, Social Impact Center, and the Hemophilia Foundation of Northern California, to name a few, heard about the value of third-party certification.
Despite limitations on travel, PFC was able to certify four new businesses to the PFC standard, including four laboratories through the dual PFC/ISO 17025 accreditation program with A2LA. Dual certification was earned by PhytaTech (Kaycha Labs), Viridis Laboratories, Keystone State Testing, and CannaSafe Analytics. CannaSafe Analytics also obtained the first PFC Health and Sanitation certification.
Six companies with pending certification are expected to complete it in 2021: YouGroGurl, Nuka Foods, The Botanical Company, ForwardGro, ForwardExtract, and PA Options for Wellness.
The PFC standard was revamped in 2020 to meet today’s industry needs, and the new standard is currently being reviewed and approved by the PFC Review Board.
In addition to updating the PFC Standard, by the end of the year PFC will finish updates to some of the State Compliance Training courses, including Pennsylvania, Maryland, and the District of Columbia. PFC is also in the process of completing updates to our Core Cannabis Training and National Cannabis Standards Training.
ASA Updates Medical Cannabis Travel Guide
The pandemic has limited travel for many people, but for medical cannabis patients who are embarking on trips, it is still important to be aware of the legal aspects.
Following the 2020 general election, there are now 48 US states and four territories with some form of a medical cannabis access, as well as 13 states and the District of Columbia that now permit adult-use.
ASA has updated its Medical Cannabis Patient’s Guide for US Travel with the new changes in state laws and reciprocity between states.
Patients who travel for personal or employment reasons can find answers about how to access medical cannabis in an unfamiliar place at www.safeaccessnow.org/travel.
New ASA Podcasts Available
The new episodes include a special post-election analysis featuring ASA President and Founder Steph Sherer. The episode with Dr. Dustin Sulak covers how to pick the right strain and dose and concludes with a summary from ASA Executive Director Debbie Churgai about the United Nations decision to remove cannabis from the most restrictive schedule.
Last month, ASA Executive Director Debbie Churgai also spoke with Gina Vensel and Elizabeth Sheldon of The Vine podcast, in Episode 3. Check it out to hear Debbie share ASA's perspective on cannabis laws, policy and the current patchwork.
ASA Year-End Review Webinar
On Wednesday, December 16, at 3 pm Eastern, ASA will host a free End of Year Policy Review webinar to wrap-up the policy developments of 2020 and discuss the political situation of medical cannabis going forward into 2021. This webinar will give ASA’s analysis and provide an opportunity for your feedback on the year in medical cannabis.
The webinar will provide an overview of:
- Highlights from some of ASA’s biggest accomplishments in 2020.
- 2020 General Election Turnout and what this means for cannabis patients.
- 2020 Ballot measures and their potential impact on states medical cannabis programs.
- Expectations of the Biden-Harris administration and where we can make an impact on their policy agenda.
- Changes in the House and Senate and their impact on cannabis bills in 2021.
- A preview of ASA’s upcoming advocacy priorities and how you can get involved.
RSVP for ASA’s 2020 Year End Policy Review at www.safeaccessnow.org/policyreview20.
Activist Profile: Kenzi Riboulet-Zemouli, Barcelona, Spain
The major victory medical cannabis advocates won last month at the UN Commission on Narcotic Drugs (CND) was the result of long years of efforts by many advocates from around the world. One of the tireless champions of patient rights who worked to achieve this is Kenzi Riboulet-Zemouli, a French-Algerian researcher who lives in Barcelona.
Kenzi is one of many collaborators with ASA and other advocates who pressed the 53 member states of the CND to accept the recommendations of the World Health Organization’s expert review of cannabis and cannabis extracts. Among Kenzi’s projects is the CND Monitor website, where information about international drug scheduling is available.
Kenzi became interested in cannabis policies in 2011 as part of a general interest in the human rights problems associated with drug prohibition. That’s when he met U.S. cannabis patient-advocate Michael Krawitz, who is executive director of Veterans for Medical Cannabis Access. From Michael, Kenzi says he learned useful strategies for navigating the bureaucracy of the U.S. federal government, strategies that proved useful in wrestling with the U.N.
“The U.S. is a bureaucratic monster,” says Kenzi. “But the U.N. is a series of bureaucratic monsters.”
After meeting Michael, ASA founder and President Steph Sherer, and members of other NGOs working on drug policy in Geneva at the WHO and UN, Kenzi got drawn further into the world of international drug policy. In 2015, he decided to devote himself to the issue full time, founding a non-profit, non-partisan and non-governmental international advocacy and research organization known as FAAAT (For Alternative Approaches to Addiction, Think & do tank) that was active until last year working on policies of addiction and controlled/illicit drugs, plants, products or substances liable to produce harms or health disorders.
“I was concerned with the devastating impact of drug policies generally, the criminalization of behaviors instead of helping them manage their conditions,” says Kenzi. His awareness of the medicinal potential of cannabis dawned slowly.
“I had been influenced by the propaganda mainstreamed for almost a century,” Kenzi says. “I was aware of medical use, but thought it was for milder conditions. I was unaware of the actual pharmacological effects on many more conditions than those used by opponents to pretend that it is fake medicine.”
Then he met actual patients who were cured or managed difficult medical conditions with cannabis. Kenzi came to believe that the most pressing issues are medical access issues.
“This is an emergency, a human rights issue,” Kenzi says. “Full legalization comes after medical, after the benefits become clearer and people see how we can handle it, that will help change attitudes.”
His work with patients has changed Kenzi’s attitude about his own cannabis use. He found it useful for the insomnia that runs in his family and his anxiety, but those conditions seemed too trivial to be serious. The patients he talked to helped him see that he was actually a patient, too--another human being deserving of care and relief from suffering.
Once the WHO and UN recognize cannabis as not just medical but as a legitimate medicine, Kenzi believes the mechanism of human rights will then oblige member states to reform prohibitionist policies. The CND decision this month enables radical change in drug policy but does not directly create it because international drug scheduling and the controlling treaty are complex and interconnected. It’s not as simple as descheduling in the U.S.
“Moving cannabis out of schedule IV is the first step,” he says. “Then the treaty must change. That is up to governments to change. That takes political steps.”
The challenge is, Kenzi says, to move beyond old postcolonial concerns to a modern kind of treaty that reflects contemporary national law and is fully based on access for patients. The current approach was created by the U.S.’s “just say no” prohibitionist eradication strategy that seeks to eliminate all illicit drugs.
More systemic reform of international law will require nations to do more than opt out of the drug treaties. All countries are supposed to harmonize their laws with the Single Convention on Narcotic Drugs.
Now that this chapter with the CND draws to a close, Kenzio is turning to human rights and the environment, intellectual property and health, and the preservation of traditional medicines and cannabis cultures.
He wants to create tools for traditional cannabis communities, both rural and urban, to avoid the destruction of their cannabis-related traditions, cultures and landraces.
Action Alert: Contact Your Rep on their MORE Act Vote
Let your Representative in the House know how you feel about their vote on the historic MORE Act. Following its historic passage, Congressmembers need to hear from the medical cannabis voters they represent, no matter how they voted.
Just enter your name and address, and we'll provide you with an example letter either thanking or correcting them, based on how they voted. Add your name and your personal message so that they know we care about their votes on medical cannabis.
Take action today at www.safeaccessnow.org/more_act_passes.